Skip to content

ThromboGenics announces launch of Jetrea in Denmark and Sweden for treatment of vitreomacular traction

ThromboGenics NV and Novartis AG have announced the launch of Jetrea ocriplasmin in Denmark and Sweden for the treatment of vitreomacular traction including when associated with a macular hole of 400um or less in diameter. ThromboGencis stated in their press release that the wholesale acquisition cost of the drug will be €3,100 for a singl-use vial of 0.125mg, the recommended dose for treatment.